| answer text |
<p>The National Institute for Health and Care Excellence’s guidance on semaglutide,
the active ingredient in wegovy, for managing overweight and obesity was published
in March 2023, and updated in September 2023. It recommends semaglutide as a treatment
option for patients that meet specified eligibility criteria, and recommends that
the treatment is provided within specialist weight management services. These services
are typically provided in secondary rather than primary care settings. The Government
is committed to the safe introduction of new weight loss drugs into the National Health
Service, and is exploring ways to increase access to more people, who meet the relevant
eligibility criteria.</p>
|
 |
